PMC:7534795 / 5671-6093 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T70564","span":{"begin":28,"end":33},"obj":"Body_part"},{"id":"T71556","span":{"begin":376,"end":389},"obj":"Body_part"},{"id":"T41271","span":{"begin":413,"end":417},"obj":"Body_part"}],"attributes":[{"id":"A47603","pred":"fma_id","subj":"T70564","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A84707","pred":"fma_id","subj":"T71556","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A58565","pred":"fma_id","subj":"T41271","obj":"http://purl.org/sig/ont/fma/fma86583"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T16","span":{"begin":28,"end":33},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T53","span":{"begin":65,"end":71},"obj":"Disease"}],"attributes":[{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T85990","span":{"begin":28,"end":33},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T15304","span":{"begin":228,"end":237},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T98618","span":{"begin":376,"end":389},"obj":"http://purl.obolibrary.org/obo/PR_000001091"},{"id":"T66694","span":{"begin":402,"end":403},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T49","span":{"begin":117,"end":127},"obj":"Chemical"},{"id":"T50","span":{"begin":143,"end":154},"obj":"Chemical"},{"id":"T51","span":{"begin":223,"end":225},"obj":"Chemical"},{"id":"T53","span":{"begin":413,"end":415},"obj":"Chemical"}],"attributes":[{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_71200"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A52","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A54","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T4456","span":{"begin":228,"end":237},"obj":"http://purl.obolibrary.org/obo/GO_0023052"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}

{"project":"LitCovid-sentences","denotations":[{"id":"T32","span":{"begin":98,"end":370},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}

{"project":"2_test","denotations":[{"id":"33031856-32527304-84038805","span":{"begin":92,"end":96},"obj":"32527304"},{"id":"33031856-32527304-84038806","span":{"begin":321,"end":325},"obj":"32527304"},{"id":"33031856-32032529-84038807","span":{"begin":346,"end":350},"obj":"32032529"},{"id":"33031856-32696108-84038808","span":{"begin":365,"end":369},"obj":"32696108"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}

{"project":"LitCovid-PubTator","denotations":[{"id":"162","span":{"begin":223,"end":227},"obj":"Gene"},{"id":"163","span":{"begin":246,"end":252},"obj":"Gene"},{"id":"164","span":{"begin":257,"end":263},"obj":"Gene"},{"id":"176","span":{"begin":376,"end":389},"obj":"Gene"},{"id":"192","span":{"begin":57,"end":103},"obj":"Disease"}],"attributes":[{"id":"A162","pred":"tao:has_database_id","subj":"162","obj":"Gene:3569"},{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"Gene:6772"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"Gene:6774"},{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"Gene:3552"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:D006331"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)\nJanus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)\nAnti-interleukin-1 • Anakinra, a modified IL-1 rece"}